hengrui glp-1 Kailera Therapeutics Announces Positive Topline Data from Two Pharma Phase 3 Clinical Trials of Oral Small Molecule Receptor Agonist HRS-7535/KAI-7535 Kailera's oral GLP-1 asset hits
Pay in 4 interest-free payments of $6.38 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12

























